When we become aware of any upcoming funding opportunities that we think might be of interest they will included here.
The Myotonic Dystrophy Foundation (MDF) is pleased to announce a Request for Applications (RFA) for the Development of a Genome Editing Strategy for Myotonic Dystrophy Type 1 (DM1). Through this RFA, MDF recognizes a need to advance genome editing technology and evaluate its potential as a therapy for use in DM1.
MDF intends to issue two 2-year awards of up to $250,000 total cost for projects that address the evaluation of genome editing strategies that target the DMPK gene. The focus of the RFA is on early stage discovery and development of in vivo genome editing technologies in academic laboratories or other nonprofit research institutions, utilizing state-of-the-art knowledge.
Collaborations between experts in genome editing technologies and those with strong track records in myotonic dystrophy research are strongly encouraged.Find out more – www.myotonic.org